NIH awards $4.8m grant to Sequella
The three new grants, combined with other grants renewed for 2011, brings total non dilutive R&D funding for 2011 to $4.8m, with an additional $3.3m committed for future
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
PGXL Laboratories provides pharmacogenetic testing and interpretive services. It has developed CYP2C9/VKORC1 tests for accurate anticoagulant dosing. Along with its clinical practice, PGXL performs contract research for manufacturers